S&P 500   4,225.05 (+1.08%)
DOW   33,115.52 (+0.63%)
QQQ   352.29 (+1.24%)
AAPL   179.98 (+1.54%)
MSFT   331.96 (+1.09%)
META   273.40 (+3.28%)
GOOGL   123.48 (+0.50%)
AMZN   123.28 (+2.24%)
TSLA   208.38 (+2.18%)
NVDA   398.85 (+5.42%)
NIO   7.59 (+0.80%)
BABA   83.74 (+5.27%)
AMD   120.31 (+1.78%)
T   15.80 (+0.45%)
F   12.12 (+1.00%)
MU   69.24 (+1.52%)
CGC   0.83 (-0.61%)
GE   104.97 (+3.39%)
DIS   88.62 (+0.75%)
AMC   4.61 (+2.44%)
PFE   38.02 (+0.00%)
PYPL   63.16 (+1.89%)
NFLX   404.18 (+2.26%)
S&P 500   4,225.05 (+1.08%)
DOW   33,115.52 (+0.63%)
QQQ   352.29 (+1.24%)
AAPL   179.98 (+1.54%)
MSFT   331.96 (+1.09%)
META   273.40 (+3.28%)
GOOGL   123.48 (+0.50%)
AMZN   123.28 (+2.24%)
TSLA   208.38 (+2.18%)
NVDA   398.85 (+5.42%)
NIO   7.59 (+0.80%)
BABA   83.74 (+5.27%)
AMD   120.31 (+1.78%)
T   15.80 (+0.45%)
F   12.12 (+1.00%)
MU   69.24 (+1.52%)
CGC   0.83 (-0.61%)
GE   104.97 (+3.39%)
DIS   88.62 (+0.75%)
AMC   4.61 (+2.44%)
PFE   38.02 (+0.00%)
PYPL   63.16 (+1.89%)
NFLX   404.18 (+2.26%)
S&P 500   4,225.05 (+1.08%)
DOW   33,115.52 (+0.63%)
QQQ   352.29 (+1.24%)
AAPL   179.98 (+1.54%)
MSFT   331.96 (+1.09%)
META   273.40 (+3.28%)
GOOGL   123.48 (+0.50%)
AMZN   123.28 (+2.24%)
TSLA   208.38 (+2.18%)
NVDA   398.85 (+5.42%)
NIO   7.59 (+0.80%)
BABA   83.74 (+5.27%)
AMD   120.31 (+1.78%)
T   15.80 (+0.45%)
F   12.12 (+1.00%)
MU   69.24 (+1.52%)
CGC   0.83 (-0.61%)
GE   104.97 (+3.39%)
DIS   88.62 (+0.75%)
AMC   4.61 (+2.44%)
PFE   38.02 (+0.00%)
PYPL   63.16 (+1.89%)
NFLX   404.18 (+2.26%)
S&P 500   4,225.05 (+1.08%)
DOW   33,115.52 (+0.63%)
QQQ   352.29 (+1.24%)
AAPL   179.98 (+1.54%)
MSFT   331.96 (+1.09%)
META   273.40 (+3.28%)
GOOGL   123.48 (+0.50%)
AMZN   123.28 (+2.24%)
TSLA   208.38 (+2.18%)
NVDA   398.85 (+5.42%)
NIO   7.59 (+0.80%)
BABA   83.74 (+5.27%)
AMD   120.31 (+1.78%)
T   15.80 (+0.45%)
F   12.12 (+1.00%)
MU   69.24 (+1.52%)
CGC   0.83 (-0.61%)
GE   104.97 (+3.39%)
DIS   88.62 (+0.75%)
AMC   4.61 (+2.44%)
PFE   38.02 (+0.00%)
PYPL   63.16 (+1.89%)
NFLX   404.18 (+2.26%)
NASDAQ:ORIC

ORIC Pharmaceuticals (ORIC) Stock Forecast, Price & News

$5.34
+0.30 (+5.95%)
(As of 02:32 PM ET)
Compare
Today's Range
$4.99
$5.41
50-Day Range
$4.73
$6.15
52-Week Range
$2.36
$6.85
Volume
114,335 shs
Average Volume
206,946 shs
Market Capitalization
$240.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.20

ORIC Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
147.2% Upside
$13.20 Price Target
Short Interest
Bearish
13.67% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.58
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.20) to ($2.02) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

421st out of 1,980 stocks

Pharmaceutical Preparations Industry

181st out of 978 stocks


ORIC stock logo

About ORIC Pharmaceuticals (NASDAQ:ORIC) Stock

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Receive ORIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ORIC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORIC Stock News Headlines

AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
4 Analysts Have This to Say About ORIC Pharmaceuticals
See More Headlines

ORIC Price History

ORIC Company Calendar

Last Earnings
3/16/2023
Today
6/01/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ORIC
Fax
N/A
Employees
78
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.20
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+161.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-89,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.50 per share

Miscellaneous

Free Float
42,685,000
Market Cap
$227.25 million
Optionable
Not Optionable
Beta
0.49

Key Executives

  • Dr. Richard A. Heyman Ph.D. (Age 65)
    Co-Founder, Independent Chairman & Member of Scientific Advisory Board
    Comp: $89.92k
  • Dr. Jacob M. Chacko M.B.A. (Age 43)
    M.D., Pres, CEO & Director
    Comp: $883.68k
  • Mr. Dominic G. Piscitelli CPA (Age 47)
    CPA, M.B.A., Chief Financial Officer
    Comp: $610.02k
  • Dr. Pratik S. Multani M.D. (Age 55)
    M.S., Chief Medical Officer
    Comp: $669.76k
  • Dr. Charles L. Sawyers B.A. (Age 63)
    BA, M.D., Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Scott W. Lowe Ph.D.
    Co-Founder & Member of Scientific Advisory Board
  • Dr. Lori Sickels Friedman Ph.D. (Age 58)
    Chief Scientific Officer
  • Dr. Christian V. Kuhlen Esq. (Age 49)
    J.D., M.D., Gen. Counsel
  • Mr. Daniel Iazzetti
    VP & Head of People
  • Dr. Edna Chow Maneval (Age 62)
    Sr. VP of Clinical Devel.













ORIC Stock - Frequently Asked Questions

Should I buy or sell ORIC Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ORIC Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ORIC shares.
View ORIC analyst ratings
or view top-rated stocks.

What is ORIC Pharmaceuticals' stock price forecast for 2023?

5 Wall Street research analysts have issued 12-month price targets for ORIC Pharmaceuticals' stock. Their ORIC share price forecasts range from $8.00 to $15.00. On average, they predict the company's share price to reach $13.20 in the next twelve months. This suggests a possible upside of 161.9% from the stock's current price.
View analysts price targets for ORIC
or view top-rated stocks among Wall Street analysts.

How have ORIC shares performed in 2023?

ORIC Pharmaceuticals' stock was trading at $5.89 at the beginning of the year. Since then, ORIC stock has decreased by 14.4% and is now trading at $5.04.
View the best growth stocks for 2023 here
.

When is ORIC Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ORIC earnings forecast
.

How were ORIC Pharmaceuticals' earnings last quarter?

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) announced its quarterly earnings results on Thursday, March, 16th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.04.

What other stocks do shareholders of ORIC Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ORIC Pharmaceuticals investors own include Pfizer (PFE), Intel (INTC), CrowdStrike (CRWD), Valero Energy (VLO), Hello Group (MOMO), ONEOK (OKE), DocuSign (DOCU), Vaxart (VXRT), Delta Air Lines (DAL) and Datadog (DDOG).

When did ORIC Pharmaceuticals IPO?

(ORIC) raised $75 million in an initial public offering (IPO) on Friday, April 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities served as the underwriters for the IPO.

What is ORIC Pharmaceuticals' stock symbol?

ORIC Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORIC."

Who are ORIC Pharmaceuticals' major shareholders?

ORIC Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (8.89%), Prosight Management LP (3.43%), BlackRock Inc. (1.53%), Renaissance Technologies LLC (0.76%), Geode Capital Management LLC (0.68%) and ArrowMark Colorado Holdings LLC (0.57%). Insiders that own company stock include Carl L Gordon, Dominic Piscitelli, Jacob Chacko, Orbimed Advisors Llc, Pratik S Multani, Richard A Heyman, Richard A Heyman and Richard H Scheller.
View institutional ownership trends
.

How do I buy shares of ORIC Pharmaceuticals?

Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ORIC Pharmaceuticals' stock price today?

One share of ORIC stock can currently be purchased for approximately $5.04.

How much money does ORIC Pharmaceuticals make?

ORIC Pharmaceuticals (NASDAQ:ORIC) has a market capitalization of $227.25 million. The company earns $-89,120,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis.

How can I contact ORIC Pharmaceuticals?

ORIC Pharmaceuticals' mailing address is 240 E. GRAND AVE. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.oricpharma.com. The company can be reached via phone at 650-388-5600 or via email at investors@oricpharma.com.

This page (NASDAQ:ORIC) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -